
MEDIPAL and JCR Partner on Global Licensing for GM2 Therapy JR-479
MEDIPAL Holdings and JCR Pharmaceuticals Expand Rare Disease Collaboration with Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Investigational Therapy for GM2 Gangliosidosis In a significant advancement for patients and families affected by ultra-rare lysosomal storage disorders, MEDIPAL…